Estimation of glomerular filtration rates after orthotopic liver transplantation: Evaluation of cystatin C–based equations

Thomas Gerhardt, Uwe Pöge, Birgit Stoffel‐Wagner, Manuela Ahrendt, Martin Wolff, Ulrich Spengler, Holger Palmedo, Tilman Sauerbruch, Rainer P. Woitas – 9 October 2006 – Early detection of renal dysfunction in patients after orthotopic liver transplantation is important. Creatinine‐based equations to estimate glomerular filtration rate (GFR) were found to be less accurate in liver transplant recipients than in their original populations.

Recurrence of autoimmune liver disease after liver transplantation: A systematic review

Manjushree Gautam, Rekha Cheruvattath, Vijayan Balan – 9 October 2006 – Recurrence of autoimmune liver disease in allografts has long been a topic of debate. We conducted a systematic review of the literature to examine the reported incidence of recurrence after liver transplantation of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH). The MEDLINE, EMBASE, and Cochrane electronic databases were used to identify articles.

Transthyretin‐derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver

Yo‐ichi Takei, Takahisa Gono, Masahide Yazaki, Shu‐ichi Ikeda, Toshihiko Ikegami, Yasuhiko Hashikura, Shin‐ichi Miyagawa, Yoshinobu Hoshii – 6 October 2006 – Familial amyloid polyneuropathy (FAP) is a form of hereditary generalized amyloidosis. Liver tissue explanted from FAP patients has normal structure and function, except for the production of amyloidogenic variant transthyretin (TTR), and domino liver transplantation (DLT) using grafts from FAP patients was first performed in 1995.

De novo nonalcoholic fatty liver disease after liver transplantation

Suk Seo, Kalyani Maganti, Manjit Khehra, Rajendra Ramsamooj, Alexander Tsodikov, Christopher Bowlus, John McVicar, Mark Zern, Natalie Torok – 6 October 2006 – Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retrospective analysis was performed on 68 OLT patients with donor liver biopsies and posttransplantation liver biopsies.

Contribution of hepatic adenosine A1 receptors to renal dysfunction associated with acute liver injury in rats

Zhi Ming, Yi‐Jun Fan, Xi Yang, W. Wayne Lautt – 27 September 2006 – Acute liver injury is associated with renal insufficiency, whose mechanism may be related to activation of the hepatorenal reflex. We previously showed that intrahepatic adenosine is involved in activation of the hepatorenal reflex to restrict urine production in both healthy rats and in rats with cirrhosis. The aim of the present study was to test the hypothesis that activation of intrahepatic adenosine receptors is involved in the pathogenesis of the renal insufficiency seen in acute liver injury.

Uracil‐tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial

Kiyoshi Hasegawa, Tadatoshi Takayama, Masayoshi Ijichi, Yutaka Matsuyama, Hiroshi Imamura, Keiji Sano, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi – 27 September 2006 – Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem. This randomized controlled trial evaluated whether postoperative adjuvant therapy with oral uracil‐tegafur (UFT) prevents recurrence of HCC.

Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes

Sean E. Doyle, Heidi Schreckhise, Kien Khuu‐Duong, Katherine Henderson, Robert Rosler, Harold Storey, Lena Yao, Hong Liu, Fariba Barahmand‐pour, Pallavur Sivakumar, Chung Chan, Carl Birks, Don Foster, Christopher H. Clegg, Perdita Wietzke‐Braun, Sabine Mihm, Kevin M. Klucher – 27 September 2006 – Interleukin‐28A (IL‐28A), IL‐28B and IL‐29 are a family of class II cytokines that stimulate antiviral responses through a heterodimeric receptor that is distinct from the type I interferon (IFN) receptor.

Subscribe to